Loading…

PES1 is a critical component of telomerase assembly and regulates cellular senescence

Telomerase defers the onset of telomere shortening and cellular senescence by adding telomeric repeat DNA to chromosome ends, and its activation contributes to carcinogenesis. Telomerase minimally consists of the telomerase reverse transcriptase (TERT) and the telomerase RNA (TR). However, how telom...

Full description

Saved in:
Bibliographic Details
Published in:Science advances 2019-05, Vol.5 (5), p.eaav1090
Main Authors: Cheng, Long, Yuan, Bin, Ying, Sunyang, Niu, Chang, Mai, Hongxu, Guan, Xin, Yang, Xiaohui, Teng, Yan, Lin, Jing, Huang, Junjian, Jin, Rui, Wu, Jun, Liu, Bo, Chang, Shaohong, Wang, Enqun, Zhang, Chunxia, Hou, Ning, Cheng, Xuan, Xu, Danyang, Yang, Xiao, Gao, Shan, Ye, Qinong
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Telomerase defers the onset of telomere shortening and cellular senescence by adding telomeric repeat DNA to chromosome ends, and its activation contributes to carcinogenesis. Telomerase minimally consists of the telomerase reverse transcriptase (TERT) and the telomerase RNA (TR). However, how telomerase assembles is largely unknown. Here, we demonstrate that PES1 (Pescadillo), a protein overexpressed in many cancers, forms a complex with TERT and TR through direct interaction with TERT, regulating telomerase activity, telomere length maintenance, and senescence. PES1 does not interact with the previously reported telomerase components Reptin, Pontin, p23, and Hsp90. PES1 facilitates telomerase assembly by promoting direct interaction between TERT and TR without affecting TERT and TR levels. PES1 expression correlates positively with telomerase activity and negatively with senescence in patients with breast cancer. Thus, we identify a previously unknown telomerase complex, and targeting PES1 may open a new avenue for cancer therapy.
ISSN:2375-2548
2375-2548
DOI:10.1126/sciadv.aav1090